首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2702篇
  免费   170篇
  国内免费   28篇
耳鼻咽喉   23篇
儿科学   40篇
妇产科学   11篇
基础医学   109篇
口腔科学   1篇
临床医学   293篇
内科学   330篇
皮肤病学   1篇
神经病学   415篇
特种医学   527篇
外科学   803篇
综合类   227篇
预防医学   29篇
眼科学   11篇
药学   54篇
中国医学   11篇
肿瘤学   15篇
  2023年   26篇
  2022年   55篇
  2021年   67篇
  2020年   68篇
  2019年   46篇
  2018年   59篇
  2017年   75篇
  2016年   87篇
  2015年   115篇
  2014年   192篇
  2013年   201篇
  2012年   177篇
  2011年   166篇
  2010年   105篇
  2009年   152篇
  2008年   147篇
  2007年   161篇
  2006年   134篇
  2005年   124篇
  2004年   87篇
  2003年   76篇
  2002年   45篇
  2001年   64篇
  2000年   46篇
  1999年   52篇
  1998年   35篇
  1997年   39篇
  1996年   35篇
  1995年   34篇
  1994年   21篇
  1993年   20篇
  1992年   19篇
  1991年   14篇
  1990年   19篇
  1989年   13篇
  1988年   12篇
  1987年   13篇
  1986年   9篇
  1985年   13篇
  1984年   20篇
  1983年   8篇
  1982年   10篇
  1981年   8篇
  1980年   6篇
  1979年   5篇
  1978年   6篇
  1977年   4篇
  1976年   3篇
  1973年   2篇
  1972年   2篇
排序方式: 共有2900条查询结果,搜索用时 15 毫秒
1.

Objective

The aim of the study was to present the results for patients with atherosclerotic aneurysm of the descending thoracic aorta (DTA) treated with a novel thoracic stent graft.

Methods

A single-center retrospective review of prospectively collected data was performed. We extracted demographic variables as well as atherosclerotic comorbidities and operation-related and imaging-related data from patients' medical records. We estimated technical success rate, in-hospital and 30-day mortality, and mortality at the end of follow-up as well as complication and reintervention rate in our study cohort. Follow-up computed tomography angiography was performed after 1 month and 6 months and yearly thereafter.

Results

A total of 30 patients (80% male; mean age, 73.7 ± 6.33 years) were treated with Ankura Thoracic Stent Graft (Lifetech, Shenzhen, China) for DTA aneurysm from February 2014 until June 2017. Technical success of the thoracic endovascular aortic repair (TEVAR) was 97% (29/30 patients). A surgical conduit was required in one patient; in three patients, we intentionally covered the left subclavian artery because of insufficient proximal landing zone. No aorta-related deaths were recorded during follow-up. During the early postoperative period, two patients (7%) with long DTA coverage developed paralysis or paraparesis, which immediately resolved after lumbar drainage. No renal complications requiring dialysis were observed. One patient (3%) developed postoperative pulmonary infection, whereas access site complications were 7%. Two symptomatic patients treated outside instructions for use (7%) developed early type IA endoleak and one patient (3%) developed type IB endoleak; type II endoleak was recorded in 3% of the study cohort. During the 30-day postoperative period, two patients died of non-TEVAR-related causes, one of gastrointestinal bleeding and the other of pulmonary infection. During a median follow-up of 31.7 (range, 38.4) months, two more patients also died of non-TEVAR-related causes, one of stroke from carotid artery disease and the other of motor vehicle trauma. In the rest of the cohort, no other adverse events were noted.

Conclusions

This novel endograft showed early evidence of a safe, effective, and durable endoprosthesis for the treatment of DTA aneurysms.  相似文献   
2.

Objective

Although endovascular repair of abdominal aortic aneurysms (AAAs) has been demonstrated to have favorable outcomes, not all cohorts of patients with AAA fare equally well. Our goal was to investigate perioperative and 1-year outcomes in patients with end-stage renal disease (ESRD) on dialysis, who have traditionally fared worse after vascular interventions, to assess how ESRD affects outcomes in a large modern cohort of endovascular aneurysm repair (EVAR) patients.

Methods

The Vascular Quality Initiative database was queried for all patients undergoing EVAR from 2010 to 2017. ESRD patients were compared with patients not on dialysis. Propensity-matched scoring and multivariable analysis were used to isolate the effects of ESRD.

Results

Of 28,683 EVARs identified, there were 321 (1.12%) patients with ESRD on dialysis. Patients with ESRD had no difference in presenting AAA size (57.5 ± 12.7 mm vs 56.7 ± 17.2 mm; P = .44); however, they had more urgent/emergent repairs (20.6% vs 13.6%; P = .002) than those without ESRD. ESRD patients were more often younger, nonwhite, and nonobese and less likely to have commercial insurance (P < .05). ESRD patients more often had hypertension, coronary artery disease, congestive heart failure, previous lower extremity bypass, aneurysm repair, and carotid interventions (P < .05). There was no difference in the rate of concomitant procedures. Matching based on demographics, comorbidities, and operative details showed that ESRD patients had longer hospital length of stay (4.8 ± 9.4 days vs 4.1 ± 12.6 days; P = .026) and higher 30-day mortality (7% vs 2.4%; P < .001). There was no difference in cardiac, pulmonary, lower extremity, bowel, and stroke complications or return to the operating room. On multivariable analysis, ESRD was associated with 30-day mortality (odds ratio, 4.1; 95% confidence interval, 2.6-6.7; P < .001). Of the 24,750 elective EVARs, 1.04% had ESRD on dialysis. Matched data for elective EVAR show increased postoperative length of stay, hospital mortality, and 30-day mortality for ESRD patients on dialysis compared with those who are not. There was no association with postoperative myocardial infarction or pulmonary complications. At 1 year, patients with ESRD on dialysis had worse survival (78% vs 94%; P < .001), and ESRD was associated with higher mortality (hazard ratio, 3.3; 95% confidence interval, 2.5-4.2; P < .001).

Conclusions

Among patients undergoing EVAR, ESRD is independently associated with higher perioperative and 1-year mortality despite not being associated with higher postoperative complications. This should be taken into account during informed consent for EVAR and risk-benefit considerations in this high-risk population, particularly for elective repair.  相似文献   
3.
目的 总结小脑前下动脉瘤的临床和影像学特点,以及手术夹闭与介入治疗两种方法的治疗效果。 方法 回顾性分析首都医科大学附属北京天坛医院神经外科2012年1月-2019年12月收治的小脑前 下动脉瘤患者的基线信息、临床表现、动脉瘤特点、治疗方式和治疗效果。 结果 共收治11例小脑前下动脉瘤患者,其中显微外科手术夹闭动脉瘤5例,治愈率100%,术后2例 (40%)出现不完全性失语和手术侧面瘫,随访均无复发;介入治疗6例,5例(83.3%)完全栓塞动脉 瘤,其中2例(33.3%)闭塞动脉瘤远端载瘤动脉,1例(16.7%)栓塞治疗失败,术后1例(16.7%)出现 记忆力下降,1例(16.7%)出院1个月后动脉瘤破裂,并最终死亡。 结论 对于小脑前下动脉瘤,积极干预对于挽救患者生命意义重大,开颅手术夹闭和介入治疗都是 可选的治疗方式,两者均效果确切。  相似文献   
4.
目的:采用浅低温不停循环优先重建弓部血管结合术中支架阻断技术治疗急性Stanford A型主动脉夹层,并与传统孙氏手术进行比较,评估其效果和安全性。方法:回顾性分析2017年1月至2018年12月山东省临沂市人民医院心脏血管外科手术治疗的40例急性A型主动脉夹层患者的资料,其中21例在浅低温不停循环下,采用优先重建弓部血管结合术中支架阻断技术进行改良的孙氏手术治疗,19例采用传统的孙氏手术治疗。统计分析患者术中、术后的相关指标及并发症情况。结果:与传统的孙氏手术相比,改良组在术中阻断时间[(218.63±27.86)min比(101.52±17.23)min]、停循环时间[(1174.74±183.65)s比(43.19±8.32)s]、体外循环时间[(218.63±27.86)min比(194.19±24.25)min]、术后并发症(14次比6次)、术后呼吸机辅助时间[(72.89±45.57)h比(29.86±32.3)h]及围术期输血量[(1332.63±301.55)ml比(991.90±323.23)ml]等方面存在明显优势,差异有统计学意义(P均<0.05)。手术后清醒时间方面,改良组优于传统组,但差异无统计学意义。结论:采用浅低温不停循环优先重建弓部血管结合术中支架阻断技术治疗急性A型主动脉夹层是安全、有效的,可以明显改善患者预后,减少并发症的发生。  相似文献   
5.
Background and purposeThe trans-cell approach using a low-profile visualized intraluminal support (LVIS) device is sometimes used for aneurysm coil embolization. However, factors related to microcatheter passage remain uninvestigated. We aimed to examine in-vitro factors related to microcatheter passage using the trans-cell approach with an LVIS.MethodsSilicone vessel models (inner diameter, 4 mm) were created with different bend segments and a 4-mm hole assuming an aneurysm neck on the side of the greater curvature. The LVIS Blue (4.5 × 32 mm) was deployed at the bend segment, and passability on the trans-cell surface was evaluated by passing the microcatheter along the micro guidewire. A total of 800 passage experiments were performed using two types of microcatheter, ten types of silicone vessel, four cell widths, five cells with the same LVIS device, and two micro guidewire directions in the aneurysm.ResultsThe Headway Duo microcatheter (35.5%, 142/400) tended to have better passability compared with the Headway 17 microcatheter (29.3%, 117/400) (p = 0.070). As the cell width and angle between the trans-cell surface and microcatheter direction increased, passability significantly increased (p = 0.027 and p < 0.001, respectively). There was no significant difference in passability when the micro guidewire was directed to the proximal side versus the distal side (p = 0.45).ConclusionsA large cell width and an obtuse angle between the trans-cell surface and microcatheter direction facilitated good passability. Although statistically marginal, microcatheters with small ledges and small tips had relatively good passability.  相似文献   
6.
IntroductionRates of aneurysm occlusion with the pipeline embolization device (PED) has varied widely in the literature from 55.7% to 93.3% at 6 months, which may reflect a difference in technique including sizing and number of devices used.Methods140 cases at our institution were retrospectively reviewed, and aneurysms treated with a single PED vs. multiple were compared.ResultsComplete aneurysm occlusion was achieved in 86.9% at 6 months, 91.8% at 1 year, and 97.6% at longest follow-up. Retreatment with an additional device was required in 7 (5.1%). Major and minor complication rate within 30 days was 1.4% and 5.0%, and at greater than 30 days was 0.8% and 3.1%.Patients treated with multiple PEDs had significantly higher rates of aneurysm occlusion at 6 months (92.9% vs. 75.6%, p = 0.017) and 12 months (98.4% vs. 81.1%, p = 0.014), with no difference in complications. The two groups were similar aside from a higher number of ophthalmic and paraophthalmic aneurysms treated with multiple PEDs (23.4% vs. 6.5%, p = 0.004; and 35.1% vs. 17.4%, p = 0.020), and more posterior communicating artery and recurrent aneurysms treated with a single PED (28.3% vs. 3.2%, p = 0.001; 23.9% vs. 8.5%, p = 0.031). The use of multiple PEDs was found to be an independent predictor of aneurysm occlusion in a multivariate analysis (p = 0.015).ConclusionsThe use of multiple PEDs for intracranial aneurysms leads to significantly higher occlusion rates without added morbidity. This benefit is particularly appropriate for ophthalmic segment aneurysms, while more distal segments with eloquent perforating branches should be managed with caution.  相似文献   
7.
感染性腹主动脉瘤(IAAA)是由于各种致病菌感染所致的一类特殊类型的动脉瘤。IAAA发病急、病情进展迅速、瘤体易于破裂、临床预后差,因此对其早诊早治十分关键。依据典型病史、实验室检查、CTA影像、术中所见、血培养或组织培养阳性结果可做出诊断。诊断明确后,应在足量应用抗生素的基础上尽早手术治疗。但有关抗生素具体使用方案、手术方案等治疗选择上尚未达成一致。目前推荐术后用抗生素至少6个月以上。伴随微创技术的发展,腔内修复术治疗IAAA的比例越来越高,且短期效果良好,未来有望成为首选的手术方式。  相似文献   
8.
于楠楠  赵晓敏  于英 《中华护理杂志》2021,56(11):1710-1713
总结1例布鲁氏菌感染性腹主动脉假性动脉瘤患者的围术期护理经验。护理要点:做好传染病患者的隔离防护管理和心理建设;手术前控制血压、疼痛和体温,卧床期间做好预防血栓指导;术后严格控制血压和腹内压,做好引流管护理,根据疾病特点做好腹壁疝、下肢动脉栓塞的观察护理和预防布鲁氏杆菌病复发指导。经过40 d精心治疗和护理,患者康复出院。微信、电话随访1年,患者恢复良好。  相似文献   
9.
Flow diverter devices have become a routine first-line option for treatment of an increasing population of intracranial aneurysms at many neurovascular centers. Despite the promising results of flow diverter stents on anterior circulation, incomplete occlusion on the presence of fetal posterior circulation has been described on several reports. Here we describe a novel technical alternative to conventional flow diversion approach for this specific subgroup of aneurysms using the low-profile flow diverter, Silk Vista Baby. The device was selectively placed into the fetal type posterior cerebral artery in half-T configuration for the treatment of a posterior communicating aneurysm using a transcirculation approach through the anterior communicating artery. This represents a useful and effective technique and should be considered when encountering the above-described situation.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号